Contemporary Pediatrics week in review: Nirsevimab recommendation, AAP updates, and more
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Image Credit: Contemporary Pediatrics
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, October 23 to Friday, October 27, 2023) and click on each link to read and watch anything you may have missed.
1.) Steven Selbst, MD, discusses ED trends, highlights mental health admissions
While at the 2023 American Academy of Pediatrics National Conference & Exhibition, Steven Selbst, MD, spoke with Contemporary Pediatrics® about current trends in pediatric emergency medicine, and highlighted the ongoing mental health crisis.
Click here for the full article.
2.) Delta-8 accessibility to minors online
In recent research highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition, investigators sought to evaluate the level of access and marketing of Delta-8 THC (D8) to minors online.
Click here for the full article.
3.) Lessons in asking patients' gender identity and sexual orientation
A recent study presented at the 2023 American Academy of Pediatrics National Conference & Exhibition evaluated how clinicians can ask patients' sexual orientation and gender identity for EHR documentation.
Click here for the full article.
4.) Negotiating to get paid what you deserve
Susan J. Kressly, MD, FAAP, shares tips and aspects of her session, "How to Ensure You Will Be Paid What You’re Worth," presented at the 2023 American Academy of Pediatrics National Conference & Exhibition, in this Contemporary Pediatrics® interview.
Click here to watch the full interview.
5.) CDC recommends nirsevimab be prioritized for highest-risk infants amid limited availability
The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.
